Plain-English translation of NCT05937438 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new approach for people who have had surgery to remove esophageal cancer. After surgery, patients typically receive radiation therapy to kill any remaining cancer cells. This trial investigates whether adding immunotherapy — a treatment that helps your immune system fight cancer — alongside radiation therapy works better than radiation therapy alone.
Even after surgery to remove esophageal cancer, cancer cells can sometimes remain and come back. Doctors want to find the most effective way to prevent this from happening. This medication is designed to help your body's own immune system recognize and destroy any hidden cancer cells, and this trial will test whether combining it with radiation gives better results.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to one of two groups. Both groups receive radiation therapy after surgery, but one group will also receive the new immunotherapy treatment. You will have imaging scans and blood tests before treatment begins to assess your health and tumor characteristics. During the treatment phase, you'll visit the hospital regularly for radiation sessions and immunotherapy infusions, with follow-up visits to monitor how you're doing and watch for any side effects.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
China